CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1) : Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)

Trial Profile

CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1) : Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Hyaluronidase (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CONSISTENT 1
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Oct 2014 Secondary endpoints, inclusion exclusion criteria and treatment table modified according to ClinicalTrials.gov record.
    • 18 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top